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The treatment of malignant hematological disorders is 
still challenging, particularly in cases of refractory diseases. 
Although hematopoietic stem cell transplantation is a 
potentially curative option, it has been associated with a 
transplant-related mortality rate of 20–25% [1]. The 
technique of adoptive T cell transfer has gained significant 
focus in the field of hematology in recent years. Chimeric 
antigen receptor T cell (CAR-T cell) therapy is a novel 
immunotherapy technique in which T lymphocytes are 
engineered with synthetic receptors known as the chimeric 
antigen receptors (CAR). This engineered effector CAR-T 
cell is capable of recognizing and eliminating cancer cells. 
It performs this function independent of the major 
histocompatibility molecules. CAR-T cell therapy is being 
used for the treatment of hematological malignancies, such 
as acute lymphoblastic leukemia, acute myeloid leukemia, 
lymphomas, and multiple myeloma.
With the advent of the use of retroviral vectors and T 
cell engineering, the first generation of CAR-T cells was 
developed in 1990 [2]. Due to their short half-life, the first 
generation of CAR-T cells was not very efficacious. However, 
almost a decade later, a co-stimulatory domain was developed, 
which set forth the development of second generation 
CAR-T cells and eventually, in 2003, a product targeting 
CD19 was developed [3]. In 2011, these CAR-T cells were 
successfully used in a patient with acute lymphoblastic 
leukemia. Currently, two therapies of US Food and Drug 
Administration (FDA) approved CAR-T cells are available, 
which include the use of axicabtagene ciloleucel (KTE-C19) 
and tisagenlecleucel (CTL019) [4]. Axicabtagene ciloleucel 
and tisagenlecleucel have been approved for relapsed/ 
refractory conditions of Non-Hodgkin’s lymphoma in young 
adults and B-acute lymphoblastic leukemia in pediatric and 
adult patients, respectively. The most recent data obtained 
from the ZUMA-1 study presented at the American Society 
of Clinical Oncology in 2018 showed that, after therapy, 
a complete response rate of 58% at 15.1 months was observed 
in patients with diffuse large B-cell lymphoma [5]. The 
efficacy data of the phase II single-arm study on 
tisagenlecleucel showed that a complete remission had 
occurred in 93% and 58% of patients at one month and 
twelve months, respectively [6]. 
Another ideal chimeric receptor antigen that has been 
focused upon in recent times for the treatment of multiple 
myeloma is the B cell maturation antigen (BCMA). BCMA 
or CD269 is the seventeenth member of the tumor necrosis 
factor superfamily (TNFRSF17) [7]. The main role of BCMA 
is to regulate B cell maturation and survival during their 
differentiation into plasma cells. It is ubiquitously expressed 
on members of the B cell lineages, which include 
plasmablasts and plasma cells, but not on hematopoietic 
stem cells and naïve B cells. In 2016, Kochenderfer et al. 
[8] reported the results of the first clinical trial conducted 
on humans on the safety and efficacy of second generation 
anti-BCMA-CAR with CD3/CD28 signaling domains. 
Twelve patients were enrolled in the study and received 
a single dose of CAR-BCMA T cells, which was subsequently 
escalated for four levels as follows: 0.3, 1, 3, and 9×106 
CAR-T cells/kg body weight. Effective clinical responses 
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were seen at higher dose levels (3 and 9×106 cells/kg). This 
trial provided evidence on the anti-myeloma activity of 
CAR-BCMA cells and opened avenues for subsequent trials 
to employ immunotherapy as a treatment option for multiple 
myeloma.
Based on the successful outcome of CAR-T cell therapy 
for B cell malignancies, various groups started working on 
cellular or antibody-based immunotherapies for acute 
myeloid leukemia (AML). The CD33 antigen, which is 
expressed on healthy myeloid and myeloid progenitor cells 
with 90% expression in myeloid leukemic blast cells, is 
a potential target for these immunotherapies. This antigen 
has been targeted previously when a humanized drug- 
conjugated anti-CD33 antibody (Gemtuzumab) was developed 
and approved by FDA in 2000 [9]. In 2010, it was withdrawn 
from the European and US markets due to resulting 
complications of bone marrow toxicity and veno-occlusive 
disease. However, it was reintroduced in 2018, after Hills 
et al. [10] published a meta-analysis suggesting that a low 
fractionated dose of Gemtuzumab in combination with 
chemotherapy had improved overall survival in patients 
with AML. Because of this response and the increased 
expression of CD33 on myeloid cells, many clinical trials 
are underway on anti-CD33 CAR therapy. 
There has been considerable progress on the application 
of CAR-T cell therapy in recent decades, although, with 
associated toxicities. The maximum toxicity is observed in 
the cytokine release syndrome (CRS) associated with 
anti-tumor activity in which the patients may develop 
symptoms such as high-grade fever, hypoxia, hypotension 
or mild flu [11]. Another complication associated with this 
is the tumor lysis syndrome caused due to a rapid and massive 
destruction of cancer cells [12]. The macrophage activation 
syndrome is another life threatening complication resulting 
in systemic inflammatory response and pancytopenia with 
an unknown mechanism of action [13]. 
In order to decrease the toxicities associated with this 
therapy, the patients must undergo a thorough physical 
evaluation and its profile should include an assessment of 
cardiac function, bone marrow examination and graft versus 
host disease status. Tumor lysis protocol is started 
preemptively in patients with bulky disease. At the time 
of infusion, aggressive hemodynamic assessment and 
supportive care should be carried out by evaluating complete 
blood counts, metabolic panel, and markers for tumor lysis. 
Cytopenias resulting from CAR-T cell infusion can be 
managed with transfusion support and administration of 
growth factor. For the cytokine release syndrome, Tocilizumab 
(IL-6 receptor antagonist) is being used extensively as an 
off-label therapy in patients who have developed this 
catastrophic complication [14]. Other therapies for the 
treatment of CRS include the use of corticosteroids, 
siltuximab and etanercept. 
The use of CAR-T cell therapy is the future in the 
treatment of hematological malignancies. Currently their 
role is limited to a refractory/relapsed setting but soon this 
option will be incorporated in treatment paradigms at 
multiple points. Adverse events include the development 
of CRS, which is still a challenge preventing its widespread 
use. Cutting-edge bench research is required to improve 
the effectiveness of this therapy that can provide physicians 
and patients a better chance at eradicating hematological 
cancers.
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